



## Predicting targets of compounds against neurological diseases using cheminformatic methodology

This is the peer reviewed version of the following article:

*Original:*

Nikolic, K., Mavridis, L., Bautista Aguilera, O.M., Marco Contelles, J., Stark, H., Do Carmo Carreiras, M., et al. (2015). Predicting targets of compounds against neurological diseases using cheminformatic methodology. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 29(2), 183-198 [10.1007/s10822-014-9816-1].

*Availability:*

This version is available <http://hdl.handle.net/11365/1010028> since 2017-06-19T16:57:56Z

*Published:*

DOI:10.1007/s10822-014-9816-1

*Terms of use:*

Open Access

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. Works made available under a Creative Commons license can be used according to the terms and conditions of said license.

For all terms of use and more information see the publisher's website.

(Article begins on next page)

# Predicting targets of compounds against neurological diseases using cheminformatic methodology

Katarina Nikolic<sup>1</sup>, Lazaros Mavridis<sup>2</sup>, Oscar M. Bautista-Aguilera<sup>3</sup>, José Marco-Contelles<sup>3</sup>, Holger Stark<sup>4</sup>, Maria do Carmo Carreiras<sup>5</sup>, Ilaria Rossi<sup>6</sup>, Paola Massarelli<sup>6</sup>, Danica Agbaba<sup>1</sup>, Rona R. Ramsay<sup>2</sup>, and John B. O. Mitchell<sup>2</sup>

<sup>1</sup>Institute of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia

<sup>2</sup>Biomedical Sciences Research Complex and EaStCHEM School of Chemistry, University of St Andrews, St Andrews, Scotland, KY16 9ST, UK

<sup>3</sup>Laboratorio de Química Médica, Instituto de Química Orgánica General, Consejo Superior de Investigaciones Científicas, C/Juan de la Cierva 3, 28006 Madrid, Spain

<sup>4</sup>Heinrich Heine University, Institute of Pharmaceutical and Medicinal Chemistry, Universitaetsstr. 1, 40225 Duesseldorf, Germany

<sup>5</sup>iMed.UL - Research Institute for Medicines and Pharmaceutical Sciences, Faculty of Pharmacy, University of Lisbon, Avda. Prof. Gama Pinto, 1649-003 Lisbon, Portugal

<sup>6</sup>Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze, University of Siena, Strada delle Scotte 6, 53100 SIENA, Italy.

## \*Corresponding Author:

Katarina Nikolic PhD Pharm,  
Department of Pharmaceutical Chemistry  
Faculty of Pharmacy, University of Belgrade  
Vojvode Stepe 450  
11000 Belgrade, Serbia  
e-mail: [knikolic@pharmacy.bg.ac.rs](mailto:knikolic@pharmacy.bg.ac.rs)  
tel. +381-63-84-30-677, +381-11-3951-259  
fax. +381-11-397-43-49

**Keywords:** multi-targeted ligands; circular fingerprints; off-target study; ChE; MAO; histamine H3 receptor; HMT

### **Abbreviations**

AD: Alzheimer's disease

AChE: acetylcholinesterase

BuChE: butyrylcholinesterase

CFP: Circular Fingerprint

3D-QSAR – 3D-quantitative structure-activity relationship

EDTA: ethylenediaminetetraacetic acid

FP: false positive

GSK-3: glycogen synthase kinase 3

HMT: histamine N-methyltransferase

H<sub>3</sub>R: histamine H<sub>3</sub>-receptor

5-HT<sub>1a</sub>: 5-hydroxytryptamine-<sub>1a</sub> (serotonin)

5-HT<sub>2a</sub>: 5-hydroxytryptamine-<sub>2a</sub> (serotonin)

5-HT<sub>2c</sub>: 5-hydroxytryptamine-<sub>2c</sub> (serotonin)

MAO-A: monoamine oxidase A

MAO-B: monoamine oxidase B

MCC: Matthews Correlation Coefficient

MTDL: multi-target-directed ligand

NMDA receptors: N-methyl-D-aspartate receptor

nAChRs: nicotinic acetylcholine receptors

8-OH-DPAT: ( $\pm$ )-8-Hydroxy-2-dipropylaminotetralin

PDE-4: phosphodiesterase 4

PD: Parkinson's disease

RMSEE: Root Mean Square Error of Estimation

RMSEP: Root Mean Square Error of Prediction

SERT: serotonin transporter

TP: true positive

Tris: tris(hydroxymethyl)aminomethane

WADA: World Anti-Doping Agency

## **Abstract**

Recently developed multi-targeted ligands are novel drug candidates able to interact with monoamine oxidase (MAO) A and B; acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE); or with histamine N-methyltransferase (HMT) and histamine H<sub>3</sub>-receptor (H<sub>3</sub>R). These proteins are drug targets in the treatment of depression, Alzheimer's disease, obsessive disorders, and Parkinson's disease.

A probabilistic method, the Parzen-Rosenblatt Window approach, was used to build a "predictor" model using data collected from the ChEMBL database. The model can be used to predict both the primary pharmaceutical target and off-targets of a compound based on its structure. Molecular structures were represented based on the circular fingerprint methodology. The same approach was used to build a "predictor" model from the DrugBank dataset to determine the main pharmacological groups of the compound. The study of off-target interactions is now recognised as crucial to the understanding of both drug action and toxicology. Primary pharmaceutical targets and off-targets for the novel multi-target ligands were examined by use of the developed cheminformatic method.

Several multi-target ligands were selected for further study, as compounds with possible additional beneficial pharmacological activities. The cheminformatic targets identifications were in agreement with four 3D-QSAR (H<sub>3</sub>R/D<sub>1</sub>R/D<sub>2</sub>R/5-HT<sub>2a</sub>R) models and by *in vitro* assays for serotonin 5-HT<sub>1a</sub> and 5-HT<sub>2a</sub> receptor binding of the most promising ligand (**71/MBA-VEG8**).

## Introduction

The diverse cerebral mechanisms implicated in neurodegenerative disorders [1] and neurological diseases [2-6] and the heterogeneous but overlapping nature of phenotypes indicated that multitarget strategies may be appropriate for the improved treatment of complex brain diseases. It is now accepted that drug action can involve plural targets and that polypharmacology – interacting with multiple targets to address disease in more subtle and effective ways – will be a key pharmacological concept in future.

**MTDL approach** [7-9] has been applied for development of CNS drugs with improved efficacy compared to their precursors, such as dopamine D<sub>2</sub>/D<sub>3</sub>/5-HT<sub>2A</sub> antagonism plus 5-HT<sub>1A</sub> partial agonism or dual **PDE-4/ GSK-3 inhibitors** for therapy of schizophrenia [10-12], monoamine reuptake inhibition plus 5-HT<sub>2C</sub> antagonist properties for tricyclic antidepressants [13-15], multi-target AChE/BuChE/MAO-A/MAO-B inhibitors for therapy of neurodegenerative Alzheimer's (AD) and Parkinson's diseases (PD) [7, 16, 17], and range of CNS drug candidates with additional activity on various targets [18-20]. The potential clinical advantages of novel classes of multi-target agents are efficacy and speed of action, improved tolerance, and therapeutic range [8, 9, 13]. Therefore, development of multi-targeted compounds, with selective ranges of cross-reactivity, as novel drug candidates against neurological diseases was one of the main aims of our recent studies [21-35].

Understanding how the neurotransmitter systems interact is also important in optimizing therapeutic strategies. Pharmacological intervention on one will often influence another, such as the well-established serotonin-dopamine interaction [36, 37] or the dopamine-

glutamate interaction [38, 39]. This is a second reason to design compounds with specific, known cross-reactivity. An example of a drug with activity on different neurotransmitter systems is the cognitive enhancer, memantine, that binds as an uncompetitive antagonist at glutamatergic NMDA receptors [40] inhibiting the influx of  $\text{Ca}^{2+}$  ions that would result in neuronal excitotoxicity. Memantine also acts as a non-competitive antagonist at the 5-HT<sub>3</sub> receptor and binds to dopamine D<sub>2</sub> receptors and nAChRs [41].

Many compounds already in databases have been investigated for multiple targets as part of drug-discovery programs. Mining this information can provide experimental information useful for building pharmacophores. Data for three groups of new dual or multi-target compounds were also used in this process and to develop 3D-QSAR models for activity evaluation at the selected targets. The first group contains novel carbonitrile-aminoheterocyclic inhibitors of both MAO A and B enzymes [21]. More selective MAO A inhibition was observed for dicarbonitrile aminofuran derivatives of the dataset [21]. The second group includes acetylene/indol/piperidines [22-25] and pyridine derivatives [26, 27], as compounds with appreciable inhibitory profile for MAO, AChE, and BuChE. These agents are potentially effective multi-targeted ligands in therapy for Alzheimer's disease [42, 43].

The third group contains the recently synthesised multipotent histamine H<sub>3</sub>R antagonists that simultaneously possess strong inhibitory potency on catabolic HMT enzyme [28, 29]. These compounds are dual acting procognitive agents with possible beneficial effects in many psychiatric and neurodegenerative diseases [34, 35].

We have previously demonstrated that prohibited substances can be classified into athletic performance-enhancing classes using MACCS, CDK, and UFS-MACCS hybrid cheminformatics descriptors and machine learning methods including Random Forest, k-Nearest Neighbours and Naive Bayes [44-46]. *In silico* prediction of protein targets is a new research area useful for understanding molecular bioactivities, performance-enhancing effects of molecules, target predictions in early drug development and toxicology [47-54], allowing the determination of both the primary pharmaceutical target and the off-targets from the structure of a compound. *In silico* ligand-target prediction helps us both to infer and to understand molecular bioactivities of test compounds. As

well as being valuable for understanding the primary pharmaceutical roles of molecules, prediction of ligand-target associations facilitates both in silico polypharmacology and toxicology. Our interest is in predicting ligand-target associations that will allow us to define binding profile of ligand and in suggesting theoretical and experimental approaches directed towards gaining a deeper understanding of possible pharmacological effects. Our novel methodology, based on Circular Fingerprint (CFP) descriptors of compounds [55] and information data mined in the ChEMBL database, was very successfully applied in prediction of unexplored compound-to-target associations using a set of the WADA prohibited compounds [56]. A similar approach [56] was now applied to determine primary pharmaceutical targets and off-targets for our novel multi-target ligands (**1-134**) [21-29] as a crucial step in understanding the pharmacological and toxicological profiles of these novel compounds. Incorporation of target predictions into our drug design workflow represents one of the main advances of this study.

The publicly available ChEMBL database [57] contains bioactivity data for hundreds of thousands of different molecules on thousands of protein targets. When this information is combined with data from sources such as DrugBank [58], results can also be associated with specific biological and pharmacological activities. One of the first steps of our methodology is to apply a clustering algorithm capable of identifying structurally different groups of ligands and finding the optimum number of clusters for a given database. Those molecules, which have been examined in different assays, may have activities for more than one target. The target prediction methods presented here can predict unexplored compound-to-target associations and patterns of activity against the whole set of targets to be assessed. Our approach allows identification of novel compounds associated with a given pharmacological function.

These predictions can help to early identify any potential beneficial pharmacological effects, or unwanted side effects, of the novel multi-target agents [21-29] examined in this study. The compounds with better pharmacological activity profiles can be further examined by 3D-QSAR for their interaction with the targets, and then selected for experimental testing. Application of these cheminformatic and 3D-QSAR methods in early stage of drug discovery could significantly reduce the need for animal or human experiments. Our results can be interpreted as a quantitative assessment of protein-target

interactions that will prevent unpromising novel compounds being examined *in vitro* and *in vivo*.

## Methods

### Filtered and Refined families of the ChEMBL Dataset

The ChEMBL database presently has 8,845 targets and 1,059,559 unique compounds, which are connected with the targets, based on experimental activity data derived from 44,682 publications. Each of the targets has compounds associated with it. Each such association comes from the experimental data indicating activity of the molecule against the target. However, some molecules are found to be inactive. A compound in ChEMBL database can be associated with more than one target family. In order to predict whether a given molecule will be active against a particular target, we first applied a number of rules on the ChEMBL dataset in order to generate sets of molecules that are experimentally determined to be bioactive ( $IC_{50}$  ( $\leq 50$   $\mu M$ ),  $K_i$  ( $< 20$   $\mu M$ ),  $K_d$  ( $\leq 10$   $\mu M$ ),  $EC_{50}$  ( $\leq 40$   $\mu M$ ),  $ED_{50}$  ( $\leq 40$   $\mu M$ ), potency ( $\leq 10$   $\mu M$ ), activity ( $\geq 40\%$ ), inhibition ( $\geq 45\%$ )). These rules depend on the ranges of values against that target and the distribution of values of the relevant quantity within ChEMBL [54, 56]. This process generates bioactivity based filtered families. Our recently developed PFClust clustering [59] was applied to all the filtered ChEMBL families, which subdivided each family into smaller groups based both on ligand structure and their proven activity on a given protein target [54, 56]. The compounds were clustered on the basis of their chemical structures, described by Circular Fingerprints (CFP) [55]. This leads to a set of refined families, each consisting of a group of molecules, which share similar chemical structure and bioactivity. The refined families of the ChEMBL dataset will allow us to identify the different sets of ligands [54, 56, 59].

### Molecular fingerprints and similarities

The studied molecules are represented as CFP vectors [55]. Pairwise similarity between two molecules is calculated by Tanimoto similarity scores [60]. The obtained Tanimoto similarity scores are then transformed into probabilities (pairwise p-values) using an



appropriate kernel function. The Gaussian distribution was proven to be the best suited kernel function for the refined ChEMBL dataset [56]. In order to predict molecule-target pairs, we had to calculate how similar a given molecule  $x_i$  is to the members of family  $\omega = \{x_1, x_2, \dots, x_n\}$  using the refined ChEMBL dataset. We first calculated the distribution of  $p(t[x_i, \omega])$  between molecule  $x_i$  and the known members of  $\omega$ . The probability density function of  $p(t[x_i, \omega])$  is then estimated by use of the Parzen-Rosenblatt (PR) [61, 62] kernel density estimation method.

### Methodology validation

Our methodology is further validated by use of a fivefold Monte Carlo cross-validation for: the original ChEMBL dataset with all the compounds assigned to their label based ChEMBL families; the bioactivity-based filtered ChEMBL families; and finally the refined ChEMBL families obtained by PFClust clustering of the filtered dataset. In each cross-validation, we remove 10% of the members of each family, which are then used as a test set of queries. To investigate the relative performances using the three different definitions of families, we calculated two validation metrics. To investigate the relative performance of each methodology, we classified as a true positive (TP) a hit to the parent family from which the query compound was taken, and as false positives (FP) hits to all other families. The TPs and FPs obtained in the first four top hits for each query in all the cross-validation runs for each of the three definitions of families were used to calculate the Matthews Correlation Coefficient (MCC) [63], as a measure of prediction success. The results of the fivefold Monte Carlo cross-validation proved that the best performing model was the one based on the refined families [56].

### Identifying the off-targets of the novel multipotent compounds

We used 134 novel drug candidates (**1-134**) (Figure 1) able to interact with MAO A and B; AChE and BuChE; or with HMT and histamine H<sub>3</sub>-receptor (Table 1), as queries against the refined ChEMBL dataset [56].

**Figure 1.** General structural formulas of the examined compounds **1-134** [21-29]. Stereocenters are indicated with a star (\*).

**Table 1.** Compounds examined in this study [21-29].

**Figure 2.** Target prediction methodology applied for a query compound (**1-134**) using the refined ChEMBL dataset.

For the three classes of compounds (Figure 1: **1-134**) we used our cheminformatic workflow (Figure 2) to retrieve from the refined ChEMBL dataset the most significant families having p-values less than 0.10 ( $\text{PR-score} \leq 0.10$ ). This allows us to identify relevant biological targets for each group of studied compounds. To validate the methodology, we first checked whether these molecules have experimentally determined activities against these targets in ChEMBL. We created a matrix in which the rows were the examined compounds, the columns were the relevant families retrieved from ChEMBL, and the values were the relevant values of the Parzen-Rosenblatt function  $f(x_i, \omega)$ . Each row of this matrix was considered as a vector and we calculated the pairwise Euclidean distances between the points. The calculated distances were further used to allow PFClust to cluster the examined compounds. For each class of ligands, we performed a ChEMBL database search and a vector of PR-scores against the refined families was retrieved. Using these position vectors for each compound, we calculated the Euclidean distances between the resulting points and a similarity matrix was created. Finally, we clustered the vectors using PFClust [59].

### **3D-QSAR modeling**

Based on the ranges and distribution of obtained PR-scores for the MAO/ChE inhibitors against the refined ChEMBL dataset was decided to examine by 3D-QSAR studies all compounds with target's PR-score  $\leq 0.17$ , in order to allow for cases missed from 2D structural fingerprints. The group of compounds with the top predictions of the H<sub>3</sub>R/dopamine-D<sub>1</sub>R/dopamine-D<sub>2</sub>R/serotonin-5-HT<sub>2a</sub> targets (PR-score  $\leq 0.17$ ) was further evaluated by the corresponding 3D-QSAR (H<sub>3</sub>R/D<sub>1</sub>R/D<sub>2</sub>R/5-HT<sub>2a</sub>) models. The H<sub>3</sub>R (pKi: 5.9-10.1) activities of 35 quinoline/piperidine derivatives (Figure 1: **101-134**) [28, 29], were used for the 3D-QSAR(H<sub>3</sub>R) model building.

Also, dopamine D<sub>1</sub>R (pK<sub>i</sub>: 4.8-8.5), dopamine D<sub>2</sub>R (pK<sub>i</sub>: 5.1-8.6), and serotonin 5-HT<sub>2a</sub> (pK<sub>i</sub>: 4.0-9.7) antagonistic activities of haloperidol, clozapine, and 11 novel indol derivatives (Figure 3) [64], were used for 3D-QSAR(D<sub>1</sub>R), 3D-QSAR(D<sub>2</sub>R), and 3D-QSAR(5-HT<sub>2a</sub>) modeling.

**Figure 3. General structural formula** of the indol derivatives used for 3D-QSAR(D<sub>1</sub>R), 3D-QSAR(D<sub>2</sub>R), and 3D-QSAR(5-HT<sub>2a</sub>) modeling.

Dominant forms of all the compounds at physiological pH [65] were further used for geometry optimisation by the Hartree-Fock/3-21G method [66, 67]. The 3D-QSAR studies of the optimised molecular models were performed by use of the Pentacle 1.0.6 program [68]. The quality of the obtained 3D-QSAR (H<sub>3</sub>R/ D<sub>1</sub>R/ D<sub>2</sub>R/5-HT<sub>2a</sub>) models was examined by use of: leave-one-out cross-validation (Q<sup>2</sup>), correlation coefficient (R<sup>2</sup><sub>Observed vs. Predicted</sub>), **RMSEE of training set**, and external validation – **RMSEP of test set** [69, 70].

### ***In Vitro* Receptor Binding**

#### *General procedures*

The compound **71/MBA-VEG8** was tested for *in vitro* affinity for serotonin 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors by radioligand binding assays. The compound was dissolved in 5% DMSO. The following receptors, their tissue sources, and specific radioligands were used: (a) rat brain cortex serotonin 5-HT<sub>1A</sub> receptor, [<sup>3</sup>H]-8-OH-DPAT; (b) rat brain cortex serotonin 5-HT<sub>2A</sub> receptor, [<sup>3</sup>H]ketanserin; (c) rat brain cortex serotonin 5-HT<sub>2C</sub> receptor, [<sup>3</sup>H]mesulergine. Total and non-specific binding were determined and specific binding calculated as the difference between total and non-specific binding. Blank experiments were carried out to determine the effect of 5% DMSO on the binding and no effects were observed. Competition experiments were analyzed by PRISM 5 (GraphPadPrism<sup>®</sup>, 1992-2007, GraphPad Software, Inc., La Jolla, CA, USA) to obtain the concentration of unlabeled drug that caused 50% inhibition of ligand binding (IC<sub>50</sub>), with six concentrations of test compound, each performed in triplicate. The IC<sub>50</sub> values obtained were used to calculate apparent inhibition constants (K<sub>i</sub>) by the method of Cheng and Prussoff [71], from the following equation:  $K_i = IC_{50}/(1+S/K_D)$  where S

represents the concentration of the hot ligand used and  $K_D$  its receptor dissociation constant ( $K_D$  values, obtained by Scatchard analysis [72], were calculated for each labeled ligand).

#### *5-HT<sub>1A</sub> binding assay*

Radioligand binding assays were performed following a published procedure [73]. Cerebral cortex from male Sprague-Dawley rats (180–220 g) was homogenized in 20 volumes of ice-cold Tris-HCl buffer (50 mM, pH 7.7) with a Polytron PT10, Brinkmann Instruments (setting 5 for 15 sec), and the homogenate was centrifuged at 50000 g for 10 min. The resulting pellet was then resuspended in the same buffer, incubated for 10 min at 37 °C, and centrifuged at 50000 g for 10 min. The final pellet was resuspended in 80 volumes of the Tris-HCl buffer containing 10 µM pargyline, 4 mM CaCl<sub>2</sub>, and 0.1% ascorbate. To each assay tube was added the following: 0.1 mL of the drug dilution (0.1 mL of distilled water if no competing drug was added), 0.1 mL of [<sup>3</sup>H]-8-hydroxy-2-(di-n-propylamino)tetralin ([<sup>3</sup>H]-8-OH-DPAT) (170.0 Ci/mmol, Perkin Elmer Life Sciences, Boston, MA, USA) in the same buffer as above to achieve a final assay concentration of 0.1 nM, and 0.8 mL of resuspended membranes. The tubes were incubated for 30 min at 37°C, and the incubations were terminated by *vacuum* filtration through Whatman GF/B filters (Brandel Biomedical Research and Laboratories Inc., Gaithersburg, MD, USA). The filters were washed twice with 5 mL of ice-cold Tris-HCl buffer, and the radioactivity bound to the filters was measured by liquid scintillation spectrometer (Packard TRI-CARB<sup>®</sup> 2000CA - Packard BioScience s.r.l., Pero, Milan, Italy). Specific [<sup>3</sup>H]-8-OH-DPAT binding was defined as the difference between binding in the absence and presence of 5-HT (10 µM).

#### *5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> binding assays*

Radioligand binding assays were performed as previously reported by Herndon et al [74]. Briefly, frontal cortical regions of male Sprague-Dawley rats (180-220 g) were dissected on ice and homogenized (1:10 w/v) in ice-cold buffer solution (50 mM Tris HCl, 0.5 mM EDTA, and 10 mM MgCl<sub>2</sub> at pH 7.4) with a Polytron PT10 (setting 5 for 15 sec) and centrifuged at 3000 g for 15 min. The pellet was resuspended in buffer (1:30 w/v),

incubated at 37 °C for 15 min and then centrifuged twice more at 3000 g for 10 min (with resuspension between centrifugations). The final pellet was resuspended in buffer that also contained 0.1% ascorbate and  $10^{-5}$  M pargyline.

Assays were performed in triplicate in a 2.0 mL volume containing 5 mg wet weight of tissue and 0.4 nM [ $^3$ H]ketanserin hydrochloride (88.0 Ci/mmol; Perkin Elmer Life Sciences, Boston, MA, USA) for 5-HT<sub>2A</sub> receptor assays, and 10 mg wet weight of tissue and 1 nM [ $^3$ H]mesulergine (87.0 Ci/mmol; Amersham Biosciences Europe GmbH) for 5-HT<sub>2C</sub> receptor assays. Cinanserin (1.0  $\mu$ M) was used to define nonspecific binding in the 5-HT<sub>2A</sub> assay. In the 5-HT<sub>2C</sub> assays, mianserin (1.0  $\mu$ M) was used to define nonspecific binding, and 100 nM spiperone was added to all tubes to block binding to 5-HT<sub>2A</sub> receptors. Tubes were incubated for 15 min at 37°C, filtered on Schleicher and Schuell (Keene, NH, USA) glass fibre filters presoaked in polyethylene imine, and washed with 10 mL of ice-cold buffer. Filters were counted at an efficiency of 50%.

## Results

### Identifying the targets of the query molecules

The TPs and FPs obtained in the first four top-ranked positions for each query compound in all the cross-validation runs for each of the three definitions of families confirmed previous observations that the refined families gave a significantly better predictivity (MCC: 0.66) [56]. Thus, for each of the four classes of compounds (Figure 1: **1-134**), we examined the refined ChEMBL families using every such compound as a query. [Relative performance of the cheminformatic methodology was further tested with true positives \(TPs\) and false positives \(FPs\) ligands, selected from the examined data set.](#) Selective and potent ligands were used as TPs in the study: tacrine/donepezil (AChE/BuChE), FA-73 (MAO-B), clorgiline (MAO-A), and 18-Hetero (HMT/H<sub>3</sub>-R). As FPs were used compounds with no activity on the specific target such as: clorgiline (AChE/BuChE), tacrine/donepezil (MAO-B), tacrine/donepezil (MAO-A), and clorgiline (HMT/H<sub>3</sub>-R). For all compounds, we calculated heat map with the top predictions (PR-score  $\leq$  0.10) that summarizes the experimental validation for the most confident predictions (PR-

scores  $\leq 0.10$ ). The selected TPs and FPs confirmed very high predictive potential of the developed method. The top targets predictions for all examined compounds (Figure 1: **1-134**) by applying the cheminformatic methodology against the refined families ChEMBL are shown in Figure 4 and Supplementary Table 1. The same procedure is repeated for the queried compounds against DrugBank [58] dataset. The obtained results (Supplementary Figure 1) are then compared with ChEMBL results with the goal of associating specific biological/pharmacological activities with ligand-target interactions.

**Figure 4.** Ligand-target associations for all examined compounds (**1-134**), obtained by querying the 134 compounds against the refined ChEMBL dataset.

**Supplementary Figure 1.** Ligand-pharmacological group associations for all examined compounds (**1-134**), obtained by querying the 134 compounds against the refined DrugBank dataset.

### **MAO-inhibitors**

For the first group of novel carbonitrile-aminoheterocyclic MAO inhibitors (Figure 1: **1-17**) [21] were not predicted to interact with MAO within the top predictions (PR-score  $\leq 0.10$ ) by querying the 17 ligands against the refined ChEMBL families (Figure 4, Supplementary Table 1). Since the structures and activities of the novel class of MAO inhibitors (Figure 1: **1-17**) [21] have just recently been published and still are not included in the ChEMBL dataset our cheminformatic method couldn't find significant similarity between the query compounds (Figure 1: **1-17**) and the refined ChEMBL dataset.

For the carbonitrile-oxazole derivatives (Figure 1: **1/CN-D1a**, **2/CN-D1b**, **3/CN-D1c**, **4/CN-D1d**, **5/CN-D1e**, **6/CN-D1f**, **7/CN-D2b**) [21] affinity was predicted with a good PR-score (PR-score  $\leq 0.10$ ) for caspase-1 and caspase-7 families. These MAO inhibitors were also classified as folic acid antagonists, antimetabolites-antineoplastics or protein kinase inhibitors by applying the cheminformatic methodology against the DrugBank

dataset (Supplementary Figure 1, Supplementary Table 2). The targets retrieved from the ChEMBL data base (caspase families) were in accordance with the DrugBank results.

### **MAO/ChE-inhibitors**

The MAO/ChE inhibitors are clustered by structure into three subgroups: acetylene/indol derivatives as potent inhibitors of MAO A and MAO B (Figure 1: **44-55**) [25], the acetylene/indol/piperidines as MAO A, MAO B, AChE, and BuChE inhibitors (Figure 1: **18-43, 56-77, 79-85**) [22-24], while the pyridine derivatives are AChE and BuChE inhibitors (Figure 1: **78, 86-100**) [26, 27].

The top targets predictions for examined MAO/ChE inhibitors (Figure 1: **44-100**) by applying the cheminformatic methodology against the refined ChEMBL dataset are shown in Figure 4 and Supplementary Table 1.

The compounds in the subgroup of acetylene/indol derivatives (Figure 1: **44-55**) [25] are identified as MAO inhibitors; the acetylene/indol/piperidines (Figure 1: **18-43, 56-77, 79-85**) [22-24] are identified as MAO/ChE inhibitors; and the subgroup of pyridine derivatives (Figure 1: **78, 86-100**) [26, 27] as ChE inhibitors within the top predictions (PR-score  $\leq 0.10$ ) (Table 2). TP control were tacrine/donepezil (AChE/BuChE), FA-73 (MAO-B), and clorgiline (MAO-A), while clorgiline (AChE/BuChE), tacrine/donepezil (MAO-B), and tacrine/donepezil (MAO-A) were used as FPs. Good agreement obtained between the theoretical and the experimental results represents experimental confirmation of reliability and accuracy of the applied cheminformatic methodology.

**Table 2.** Experimental [validation](#) of the top ranked targets (PR-Scores $\leq 0.10$ ) for the MAO/ChE inhibitors class (**44-100**). a) PR-Scores are derived by applying the cheminformatic methodology against the refined ChEMBL dataset.

Compounds **31/PF96-Donz-D8, 33/PF96-Donz-D10, 34/PF96-Donz-11, 36/PF96-Donz-D13, 60/Donz-D6, 62/Donz-D8, 63/Donz-D9, and 68/MBA-71**, are identified as ligands for the histamine H<sub>3</sub> receptor by applying the cheminformatic methodology against the refined ChEMBL dataset (Table 3).

Compounds **62/Donz-D8**, **63/Donz-D9**, **67/MBA-50**, **70/MBA-73**, and **71/MBA-VEG8** are determined as ligands for dopamine D<sub>1</sub> receptors by applying the cheminformatic methodology against the refined ChEMBL dataset (Figure 5, Table 3).

Compound **63/Donz-D9** is identified as a ligand for dopamine D<sub>2</sub> receptors by applying the cheminformatic methodology against the refined ChEMBL dataset (Figure 5, Table 3).

**Figure 5.** Target prediction for **63/Donz-D9**.

Compounds **57/Don-D3**, **58/Don-D4**, **59/Don-D5**, **60/Don-D6**, **69/MBA-72**, **71/MBA-VEG8**, **82/TC4-MBA-91**, **83/MBA-98F1**, **84/MBA-98F2**, and **85/MBA-101** are identified as good ligands for serotonin 5-HT<sub>2a</sub>R receptors. Additionally, **71/MBA-VEG8** is determined as a very good ligand for 5-HT<sub>1a</sub>R, 5-HT<sub>2c</sub>R, and 5-HT<sub>5a</sub>R by applying the cheminformatic methodology against the refined ChEMBL dataset (Figure 6, Table 3).

Based on the ranges and distribution of PR-scores obtained for the MAO/ChE inhibitors against the refined ChEMBL dataset, was decided to increase the upper PR-score limit to 0.17 for further studies. A group of the selected compounds with the top predictions of the H<sub>3</sub>R/D<sub>1</sub>R/D<sub>2</sub>R/5-HT<sub>2a</sub>R targets (PR-score ≤ 0.17) were further evaluated by 3D-QSAR (H<sub>3</sub>R, D<sub>1</sub>R, D<sub>2</sub>R, 5-HT<sub>2a</sub>R) studies and by *in vitro* 5-HT<sub>1a</sub>R, 5-HT<sub>2c</sub>R, and 5-HT<sub>2a</sub>R binding assays of the most promising ligand (**71/MBA-VEG8**) (Figure 5). The top ranked targets of the ligands obtained by the cheminformatic method were in good accordance with the corresponding activities of ligands predicted by the 3D-QSAR (H<sub>3</sub>R/D<sub>1</sub>R/D<sub>2</sub>R/5-HT<sub>2a</sub>R) models (Figure 6, Table 3). These predictions are testable by future experiments.

**Table 3.** Experimental and 3D-QSAR validation of the top ranked targets for the MAO/ChE inhibitors class (**44-100**). a) PR-Scores are derived by applying the cheminformatic methodology against the refined ChEMBL dataset. b)  $pKi = \log(1/Ki)$ ,  $Ki$



[M], c)  $Ki(5\text{-HT}_{1a}\text{R}) = 1.08 \times 10^{-7} \pm 0,04 \text{ M}$ ,  $IC_{50}(5\text{-HT}_{1a}\text{R}) = 2.40 \times 10^{-7} \pm 0,10 \text{ M}$ ,  $Ki(5\text{-HT}_{2a}\text{R}) = 1.42 \times 10^{-8} \pm 0.57 \text{ M}$ ,  $IC_{50}(5\text{-HT}_{2a}\text{R}) = 1.92 \times 10^{-8} \pm 0.77 \text{ M}$ .

**Figure 6.** Target prediction for **71/MBA-VEG8**.

The *in vitro* 5-HT<sub>1a</sub>R and 5-HT<sub>2a</sub>R binding assay for **71/MBA-VEG8** determined the *Ki* for 5-HT<sub>1a</sub>R as 108 nM and the *Ki* for 5-HT<sub>2a</sub>R as 14.2 nM (Figure 7).

**Figure 7.** Concentration-response curves of compound **71/MBA-VEG8** in *in vitro* assays for 5-HT<sub>1a</sub> ( $IC_{50} 2.40 \times 10^{-7} \pm 0.10$ ) (A) and for 5-HT<sub>2a</sub> ( $IC_{50} 1.92 \times 10^{-8} \pm 0.77$ ) (B) receptor binding. The curves were generated by non-linear regression to determine the  $IC_{50}$  values. Data points are the mean  $\pm$  SD of triplicate values as described in Methods.

These results experimentally confirmed high prediction capacity of the applied cheminformatic methodology. The *in vitro* binding assay of **71/MBA-VEG8** on 5-HT<sub>2c</sub>R determined no affinity. This result can be explained by the higher PR-score for **71/MBA-VEG8** on 5-HT<sub>2c</sub>R, then on 5-HT<sub>1a</sub>R and 5-HT<sub>2a</sub>R.

The MAO/ChE inhibitors were classified as serotonin antagonists and dopamine agonists by applying the cheminformatic methodology against DrugBank dataset (Supplementary Figure 1, Supplementary Table 2). The main targets retrieved from the ChEMBL data base (5-HT<sub>1</sub>, 5-HT<sub>2</sub>, D<sub>1</sub>, D<sub>2</sub> receptors) were in agreement with the DrugBank results for the MAO/ChE inhibitors.

### **H<sub>3</sub>R/HMT/ChE ligands**

The third group (**101/1-Hetero-134/34-Hetero**) contains multipotent histamine H<sub>3</sub> receptor (H<sub>3</sub>R) antagonists with inhibiting activity on HMT enzyme [28, 29]. For several ligands of the third group, **109/9-Hetero**, **128/28-Hetero**, **131/31-Hetero**, **133/33-**

**Hetero**, **134/34-Hetero**, is experimentally determined inhibiting activity on AChE/BuChE enzymes too [29].

The top targets predictions for examined H<sub>3</sub>R/HMT/ChE ligands (Figure 1: **101/1-Hetero-134/34-Hetero**) by applying the cheminformatic methodology against the refined ChEMBL dataset are shown in Figure 4 and Supplementary Table 1.

The piperidine/quinoline derivatives (Figure 1: **101/1-Hetero-134/34-Hetero**) [28, 29] are defined as H<sub>3</sub>R/HMT ligands within the top predictions (PR-score  $\leq$  0.10) (Table 4). The **109/9-Hetero**, **131/31-Hetero**, and **133/33-Hetero** compounds are also identified as AChE/BuChE inhibitors by applying the cheminformatic methodology against the refined ChEMBL dataset (Table 4).

**Table 4.** Experimental [validation](#) of the top ranked targets (PR-Scores $\leq$ 0.10) for the H<sub>3</sub>R/HMT/ChE ligands (**101/1-Hetero-134/34-Hetero**). a) PR-Scores are derived by applying the cheminformatic methodology against the refined ChEMBL dataset.

For all top ranked targets (PR-Scores $\leq$ 0.10) of the H<sub>3</sub>R/HMT/ChE ligands are experimentally confirmed strong ligand-target affinities (Table 4). The accordance between the predicted pharmacological targets and the *in vitro* activities of the H<sub>3</sub>R/HMT/ChE ligands (Table 4) has proved high accuracy and reliability of the applied cheminformatic methodology against the refined ChEMBL dataset.

**Table 5.** List of the top ranked targets predictions (PR-Scores $\leq$ 0.10) for the H<sub>3</sub>R/HMT/ChE ligands (**101/1-Hetero-134/34-Hetero**). a) PR-Scores are derived by applying the cheminformatic methodology against the refined ChEMBL dataset.

Based on the identified off targets (Table 5) the compounds **102/2-Hetero**, **131/31-Hetero**, **132/32-Hetero**, and **133/33-Hetero** are selected for further experimental study as promising novel agents with possible beneficial effects in treatment of depression, Alzheimer's disease, and obsessive disorders.

Compounds **111/111-Hetero–124/124-Hetero** are identified as potential antiproliferative compounds against colon adenocarcinoma cells, erythroleukemia cells, lymphoma cells, and lymphocytic leukemia cells.

The H<sub>3</sub>R/HMT/ChE ligands were classified as dopamine/histamine antagonists (antipsychotic agents), serotonin antagonists (antiemetic or antipsychotic agents) by applying the cheminformatic methodology against the DrugBank dataset (Supplementary Figure 1, Supplementary Table 2.). The targets retrieved from the ChEMBL data base (H<sub>1</sub>, H<sub>3</sub>, NMDA, and D<sub>2</sub> receptors) accorded well with the DrugBank results.

## Discussion

Our current methodology has confirmed to enhance the predictive power of the CFP representations, and that the filtering and refinement of ChEMBL families enriches our results. The refined ChEMBL dataset and our protein target prediction approach could serve as a baseline for further methodologies. The developed workflow represents a truly portable methodology that can easily be used in initial phase of drug design process.

Having thus fivefold cross-validated cheminformatic approach, we used it to identify the protein targets associated with the 134 multipotent compounds against neurological diseases able to interact with MAO A and B; AChE and BuChE; or with HMT and histamine H<sub>3</sub>-receptor. Across the three classes considered, we find a combination of expected and unexpected protein targets for the examined ligands. Good agreement between the predicted pharmacological targets and the experimental results for the MAO/ChE and H<sub>3</sub>R/HMT/ChE ligands (Table 2 and 4) has proved high reliability and accuracy of the applied cheminformatic methodology.

For the MAO/ChE inhibitor, compound **71/MBA-VEG8**, the cheminformatic method has determined serotonin 5-HT<sub>1a</sub>R, 5-HT<sub>2a</sub>R, 5-HT<sub>2c</sub>R, 5-HT<sub>5a</sub>R, and D<sub>1</sub>R as possible off-targets. The compound **71/MBA-VEG8** with the top prediction of the 5-HT<sub>2a</sub>R and 5-HT<sub>1a</sub>R targets was further examined by the *in vitro* 5-HT<sub>2a</sub>R and 5-HT<sub>1a</sub>R binding assay.

The binding study has confirmed relatively strong affinity of the **71/MBA-VEG8**:  $K_i(5\text{-HT}_{2a}\text{R}) = 14.2\text{ nM}$  and  $K_i(5\text{-HT}_{1a}\text{R}) = 108\text{ nM}$  for the receptors.

Also, for set of compounds (ID: **31, 33, 34, 36, 57-60, 62, 63, 67-71, 82-85, 102**) with the top prediction of H<sub>3</sub>R/D<sub>1</sub>R/D<sub>2</sub>R/5-HT<sub>2a</sub>R off-targets, we made 3D-QSAR bioactivity evaluation, obtaining a very good accordance between the cheminformatic and 3D-QSAR (H<sub>3</sub>R/D<sub>1</sub>R/D<sub>2</sub>R/5-HT<sub>2a</sub>R) results.

The observed or predicted affinities of **63/Donz-D9, 71/MBA-VEG8, 102/2-Hetero** ligands for 5-HT<sub>2a</sub>R, D<sub>1</sub>R, D<sub>2</sub>R could be explained with similarity between **63/Donz-D9** and clozapine chemical scaffolds, as well as between **71/MBA-VEG8, 102/2-Hetero** and haloperidol chemical scaffolds (Figure 8).

**Figure 8.** Chemical scaffolds of **63/Donz-D9, 71/MBA-VEG8, 102/2-Hetero**, haloperidol, and clozapine.

Serotonin (5-HT) plays a major role in the pathophysiology and treatment of depression, anxiety, schizophrenia, and various forms of dementia including Alzheimer's disease [75]. Therefore, serotonin 5-HT<sub>1a</sub> partial agonists/antagonists and 5-HT<sub>2a</sub> antagonists have shown effectiveness in improving cognition in depression [8, 13, 15, 75], schizophrenia [14, 76-78], Alzheimer's and Parkinson's diseases [79-82].

Based on results of previous studies [76, 83] it was proposed that drugs with potent serotonin 5-HT<sub>1a</sub> or 5-HT<sub>2a</sub> antagonistic actions may improve cognition in various neurodegenerative disorders due to a association with NMDA receptors [84, 85].

Few recent studies of memantine, as a non-competitive antagonist of glutamatergic NMDA receptors [86, 87], demonstrated that this drug for treatment of AD also competitively inhibits both MAO-A and MAO-B in nanomolar range and inhibits the reuptakes of both DA and 5-HT. The mamantine induce 5-HT<sub>2a</sub> receptor-mediated head-twitch response (HTR) and head-weaving side effects [88, 89]. These abnormal behaviours developed during mamantine therapy of AD were inhibited by co-administration of haloperidol (D<sub>1</sub>/D<sub>2</sub>/5-HT<sub>2a</sub> antagonist) or ketanserine (5-HT<sub>2a</sub> antagonist) [86].

Based on all these findings is assumed that multi-potent ligands targeting AChE/MAO-A/MAO-B and also D<sub>1</sub>/D<sub>2</sub>/5-HT<sub>2a</sub>/H<sub>3</sub>, such as **63/Donz-D9** and **71/MBA-VEG8**, are promising novel drug candidates with improved efficacy and safety in treatment of Alzheimer's and related diseases.

Also, numerous pharmacological, preclinical and clinical studies proved that histamine H<sub>3</sub>R antagonists/inverse agonists facilitate the corticolimbic liberation of acetylcholine, noradrenaline, dopamine, glutamate, and serotonin [2, 3, 5] and therefore demonstrate efficacy in diverse preclinical models of cognitive deficits [90].

Therefore, H<sub>3</sub>/HMT multi-target ligands with additional affinities for D<sub>2</sub>/5-HT<sub>2a</sub>/SERT/NMDA, such as **102/2-Hetero**, **131/31-Hetero**, **132/32-Hetero**, and **133/33-Hetero**, are promising novel procognitive agents with beneficial effects in treatment of various neurodegenerative diseases.

## **Experimental**

The computations described in Methods were carried out on a custom-built computer using an Intel i3 processor @ 3.10Ghz with 4GB of RAM.

## **Competing interests**

The authors (JBOM, LM) have received funding from WADA. Other than this sponsorship, the authors declare no conflict of interest.

## **Acknowledgement**

This project has been carried out with the support of WADA. We also acknowledge financial support from the Scottish Universities Life Sciences Alliance (SULSA). OMBA and JMC thank MINECO (Spain) for a fellowship, and support (SAF2012-33304), respectively. KN and DA acknowledge project supported by the Ministry of Education and Science of the Republic of Serbia, Contract #172033. Further supports by Else Kröner-Fresenius-Stiftung, Translational Research Innovation – Pharma (TRIP), Fraunhofer-Projektgruppe für Translationale Medizin und Pharmakologie (TMP) (to HS) and the European COST Actions BM1007, CM1103 (including STSM 10295 to KN), and CM1207 are also gratefully acknowledged.

## **References**

1. Goedert M, Spillantini MGA (2006) A century of Alzheimer's disease. *Science* 314: 777–781
2. Humbert-Claude M, Morisset S, Gbahou F, Arrang JM (2007) Histamine H3 and dopamine D2 receptor-mediated [<sup>35</sup>S]GTPγ[S] binding in rat striatum: Evidence for additive effects but lack of interactions. *Biochem Pharmacol* 73: 1172-1181
3. Garduno-Torres B, Trevino M, Gutierrez R, Arias-Montano JA (2007) Presynaptic histamine H3 receptors regulate glutamate, but not GABA release in rat thalamus. *Neuropharmacology* 52: 527–535
4. Dai H, Fu Q, Shen Y, Hu W, Zhang Z, Timmerman H, Leurs R, Chen Z (2007) The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons. *Eur J Pharmacol* 563: 117–123
5. Threlfell S, Cragg SJ, Imre K, Turi GF, Coen CW, Greenfield SA (2004) HistamineH3 receptors inhibit serotonin release in substantia nigra pars reticulata. *J Neurosci* 24: 8704–8710
6. Gemkow MJ, Davenport AJ, Harich S, Ellenbroek BA, Cesura A, Hallett D (2009) The histamine H3 receptor as a therapeutic drug target for CNS disorders. *Drug Discovery Today* 14: 509-515
7. León R, Garcia AG, Marco-Contelles J (2013) Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer’s disease. *Med Res Rev* 33: 139-189
8. Millan MJ (2014) On ‘polypharmacy’ and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal. *International Journal of Neuropsychopharmacology* 17: 1009–1037
9. Anighoro A, Bajorath J, Rastelli G (2014) Polypharmacology: Challenges and opportunities in drug discovery, *J Med Chem* 57: 7874–7887, Morphy R, Rankovic Z (2005) Designed Multiple Ligands. An Emerging Drug Discovery Paradigm. *J Med Che* 48: 6523–6543
10. Roth BL, Sheffler DJ, Kroeze WK (2004) Magic Shotguns versus Magic Bullets: Selectively Non-Selective Drugs for Mood Disorders and Schizophrenia. *Nat Rev Drug Discovery* 3: 353–359
11. Lipina TV, Palomo V, Gil C, Martinez A, Roder JC (2013) Dual Inhibitor of PDE7 and GSK-3-VP1.15 Acts as Antipsychotic and Cognitive Enhancer in C57BL/6J Mice. *Neuropharmacology* 64: 205–214
12. Lipina TV, Wang M, Liu F, Roder JC (2012) Synergistic Interactions between PDE4B and GSK-3: DISC1 Mutant Mice. *Neuropharmacology* 62: 1252–1262
13. Millan MJ (2006) Multi-target strategies for the improved treatment of depressive states: conceptual foundation and neuronal substrates, drug discovery and therapeutic application. *Pharmacol Ther* 110:135–370
14. Meltzer HY, Massey BW, Horiguchi M (2012) Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. *Curr Pharm Biotechnol* 13:1572–1586
15. Quesseveur G, Nguyen HT, Gardier AM, Guiard BP (2012) 5-HT2 ligands in the treatment of anxiety and depression. *Expert Opin Investig Drugs* 21:1701–1725

16. Youdim MBH, Buccafusco JJ (2005) Multi-Functional Drugs for Various CNS Targets in the Treatment of Neurodegenerative Disorders. *Trends Pharmacol Sci* 26: 27–35
17. Tahtouh T, Elkins JM, Filippakopoulos P, Soundararajan M, Burgy G, Durieu E, Cochet C, Schmid RS, Lo DC, Delhommel F, Oberholzer AE, Pearl LH, Carreaux F, Bazureau JP, Knapp S, Meijer L (2012) Selectivity, Cocrystal Structures, and Neuroprotective Properties of Leucettines, a Family of Protein Kinase Inhibitors Derived from the Marine Sponge Alkaloid Leucettamine, *B J Med Chem* 55: 9312–9330
18. Rosini M, Antonello A, Cavalli A, Bolognesi ML, Minarini A, Marucci G, Poggesi E, Leonardi A, Melchiorre C (2003) Prazosin-related compounds. Effect of transforming the piperazinylquinazoline moiety into an aminomethyltetrahydroacridine system on the affinity for  $\alpha 1$ -adrenoreceptors. *J Med Chem* 46: 4895-4903
19. Fang L, Appenroth D, Decker M, Kiehnopf M, Roegler C, Deufel T, Fleck C, Peng S, Zhang Y, Lehmann J (2008) Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates. *J Med Chem* 51: 713-716
20. Stosel A, Schlenk M, Hinz S, Kuppers P, Heer J, Gutschow M, Muller CE (2013) Dual targeting of adenosine A2A receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones. *J Med Chem*, 56: 4580–4596, Fang L, Kraus B, Lehmann J, Heilmann J, Zhang Y, Decker M (2008) Design and synthesis of tacrine–ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates. *Bioorg Med Lett* 18: 2905-2909
21. Jiménez JJ, Mendes E, Galdeano C, Martins C, Silva DB; Marco-Contelles J, Carmo Carreiras M, Luque FJ, Ramsay RR (2014) Exploring the structural basis of the selective inhibition of monoamine oxidase A by dicarbonitrile aminoheterocycles: Role of Asn181 and Ile335 validated by spectroscopic and computational studies. *Biochim Biophys Acta* 1844: 389-397
22. Bautista-Aguilera OM, Esteban G, Bolea I, Nikolic K, Agbaba D, Moraleda I, Iriepa I, Samadi A, Soriano E, Unzeta M, Marco-Contelles J (2014) Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil–indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease. *Eur J Med Chem* 75: 82-95
23. Samadi A, Chioua M, Bolea I, de los Ríos C, Iriepa I, Moraleda I, Bastida A, Esteban G, Unzeta M, Gálvez E, Marco-Contelles J (2011) Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease. *Eur J Med Chem* 46: 4665-4668
24. Bolea I, Juárez-Jiménez J, de los Ríos C, Chioua M, Pouplana R, Javier Luque F, Unzeta M, Marco-Contelles J, Samadi A (2011) Synthesis, Biological Evaluation, and Molecular Modeling of Donepezil and N-[(5-(Benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-Nmethylprop-2-yn-1-amine Hybrids as New Multipotent Cholinesterase/Monoamine Oxidase Inhibitors for the Treatment of Alzheimer's Disease. *J Med Chem* 54: 8251–8270

25. Pérez V, Marco-Contelles J, Fernández-Álvarez E, Unzeta M (1999) Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition. *Brit J Pharmacol* 127: 869-876
26. Marco-Contelles J, Leon R, Ríos C, Guglietta A, Terencio J, Lopez MG, Garcia AG, Villarroya M (2006) Novel Multipotent Tacrine-Dihydropyridine Hybrids with Improved Acetylcholinesterase Inhibitory and Neuroprotective Activities as Potential Drugs for the Treatment of Alzheimer's Disease. *J Med Chem* 49: No. 26
27. Marco-Contelles J, Leon R, Ríos C, Samadi A, Bartolini M, Andrisano V, Huertas O, Barril X, Luque FJ, Rodriguez-Franco MI, Lopez B, Lopez MG, Garcia AG, Carmo Carreiras M, Villarroya M (2009) Tacripyrines, the First Tacrine-Dihydropyridine Hybrids, as Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease. *J Med Chem* 52: 2724–2732
28. Apelt J, Ligneau X, Pertz H, Arrang JM, Ganellin CR, Schwartz JC, Schunack W, Holger S (2002) Development of a new class of nonimidazole histamine H(3) receptor ligands with combined inhibitory histamine N-methyltransferase activity. *J Med Chem* 45: 1128-1141
29. Petroianu G, Arafat K, Sasse BC, Stark H (2006) Multiple enzyme inhibitions by histamine H3 receptor antagonists as potential procognitive agents. *Pharmazie* 61: 179-182
30. Grassmann S, Apelt J, Sippl W, Ligneau X, Pertz HH, Zhao YH, Arrang JM, Ganellin CR, Schwartz JC, Schunack W, Stark H (2003) Imidazole derivatives as a novel class of hybrid compounds with inhibitory histamine N-methyltransferase potencies and histamine H3 receptor affinities. *Bioorg Med Chem* 11: 2163-2174
31. Grassmann S, Apelt J, Ligneau X, Pertz HH, Arrang JM, Schwartz JC, Schunack W, Stark H (2004) Search for histamine H(3) receptor ligands with combined inhibitory potency at histamine N-methyltransferase: omega-piperidinoalkanamine derivatives. *Arch Pharm Med Chem* 337: 533–545
32. Apelt J, Grassmann S, Ligneau X, Pertz HH, Ganellin CR, Arrang JM, Schwartz JC, Schunack W, Stark H (2005) Search for histamine H3 receptor antagonists with combined inhibitory potency at Ntau-methyltransferase: ether derivatives. *Pharmazie* 60: 97–106
33. Ligneau X, Lin JS, Vanni-Mercier G, Jouvét M, Muir JL, Ganellin CR, Stark H, Elz S, Schunack W, Schwartz JC (1998) Neurochemical and Behavioural Effects of Ciproxifan, a Potent Histamine H3-Receptor Antagonist. *J Pharmacol Exp Ther* 287: 658-666
34. Sander K, Kottke T, Stark H (2008) Histamine H3 Receptor Antagonists Go to Clinics. *Biol Pharm Bull* 31: 2163-2181
35. Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD (2008) The histamine H3 receptor: An attractive target for the treatment of cognitive disorders. *Br J Pharmacol* 154: 1166-1181
36. Di Giovanni G, Di Matteo V, Pierucci M, Esposito E (2008) Serotonin-dopamine interaction: electrophysiological evidence. *Prog Brain Res* 172: 45-71
37. Di Matteo V, Di Giovanni G, Pierucci M, Esposito E (2008) Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies. *Prog Brain Res* 172: 7-44



38. Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. *Trends Neurosci* 13: 272-276,
39. Millan MJ (2005) N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: Novel insights and clinical perspectives. *Psychopharmacology* 179: 30-53
40. Rogawski MA, Wenk GL (2003) The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. *CNS Drug Rev* 9: 275-308
41. Cummings JL, Morstorf T, Zhong K (2014) Alzheimer's disease drug-development pipeline: Few candidates, frequent failures. *Alzheimers Res Ther* 6: 37
42. Zheng H, Youdim MBH, Fridkin M. Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy. *J Med Chem* 52: 4095-4098
43. Cavalli A, Bolognesi ML, Minarini M, Rosini V, Tumiatti M, Recanatini C, Melchiorre C (2008) Multi-target-directed ligands to combat neurodegenerative diseases. *J Med Chem* 51: 347-372
44. Cannon EO, Bender A, Palmer DS, Mitchell JBO (2006) Chemoinformatics-Based Classification of Prohibited Substances Employed for Doping in Sport. *J Chem Inf Model* 5: 2369-2380
45. Cannon EO, Mitchell JBO (2006) Classifying the World Anti-Doping Agency's 2005 Prohibited List Using the Chemistry Development Kit Fingerprint. *Lecture Notes in Bioinformatics* 5: 173-182
46. Cannon EO, Nigsch F, Mitchell JBO (2008) Novel Hybrid Ultrafast Shape Descriptor Method for use in Virtual Screening. *Chem Central J* 5: 3
47. Paolini VG, Shapland RHB, Van Hoorn WP, Mason JS, Hopkins AL (2006) Global mapping of pharmacological space. *Nat Biotechnol* 5: 805-815
48. Bender A, Scheiber J, Glick M, Davies JW, Azzaoui K, Hamon J, Urban L, Whitebread S, Jenkins JL (2007) Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. *Chem Med Chem* 5: 861-873
49. Nigsch F, Mitchell JBO (2008) Toxicological Relationships Between Proteins Obtained from Protein Target Predictions of Large Toxicity Databases. *Toxicol Appl Pharmacol* 5: 225-234
50. Nigsch F, Bender A, Jenkins JL, Mitchell JBO (2008) Ligand-Target Prediction using Winnow and Naive Bayesian Algorithms and the Implications of Overall Performance Statistics. *J Chem Inf Model* 5: 2313-2325
51. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijjer MB, Matos RC, Tran TB, Whaley R, Glennon RA, Hert J, Thomas KLH, Edwards DD, Shoichet BK, Roth BL (2009) Predicting new molecular targets for known drugs. *Nature* 2009, 5: 175-181
52. Niiijima S, Yabuuchi H, Okuno Y (2011) Cross-Target View to Feature Selection: Identification of Molecular Interaction Features in Ligand-Target Space. *J Chem Inf Model* 5, 15-24
53. Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, Jenkins JL, Lavan P, Weber E, Doak AK, Cote S, Shoichet BK, Urban L (2012) Large-scale prediction and testing of drug activity on side-effect targets. *Nature* 5: 361-367

54. Perez-Nueno VI, Venkatraman V, Mavridis L, Ritchie DW (2012) Detecting Drug Promiscuity Using Gaussian Ensemble Screening. *J Chem Inf Model* 5: 1948–1961
55. Glen RC, Bender A, Arnby CH, Carlsson L, Boyer S, Smith J (2006) Circular Fingerprints: Flexible molecular descriptors with applications from physical chemistry to ADME. *IDrugs* 9: 199-204
56. Mavridis L, Mitchell JBO (2013) Predicting the protein targets for athletic performance-enhancing substances. *J Cheminform* 5: 31
57. Gaulton A, Bellis LJ, Bento PA, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP (2012) ChEMBL: a large-scale bioactivity database for drug discovery. *Nucleic Acids Res* 5: D1100–D1107
58. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Whishart DS (2011) DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. *Nucleic Acids Res* 5: D1035–D1041
59. Mavridis L, Nath N, Mitchell JBO (2013) PFClust: A Novel Parameter Free Clustering Algorithm. *BMC Bioinformatics* 14: 213
60. Rogers DJ, Tanimoto TT (1960) A Computer Program for Classifying Plants. *Science* 5: 1115–1118
61. Parzen E (1962) On Estimation of a Probability Density Function and Mode. *Ann Math Statist* 5: 1065–1076
62. Rosenblatt M (1956) Remarks on Some Nonparametric Estimates of a Density Function. *Ann Math Statist* 5: 832–837
63. Matthews BW (1975) Comparison of the predicted and observed secondary structure of T4 phage lysozyme. *Biochim Biophys Acta* 5: 442–451
64. Hamacher A, Weigt M, Wiese M, Hoefgen B, Lehmann J, Kassack MU (2006) Dibenzazecine compounds with a novel dopamine/5HT<sub>2A</sub> receptor profile and 3D-QSAR analysis, *BMC Pharmacology* 6: No 11
65. ChemAxon MarvinSketch 5.5.1.0 program (2011) Budapest, Hungary  
[www.chemaxon.com/products.html](http://www.chemaxon.com/products.html)
66. Froese Fischer CF (1977) *The Hartree-Fock Method for Atoms: A Numerical Approach*. John Wiley and Sons, New York
67. Gaussian 98 (Revision A.7) Frisch MJ et al (1998) Gaussian Inc., Pittsburgh PA
68. Pentacle, Version 1.0.6., (2009) Molecular Discovery Ltd, Perugia, Italy  
[http://www.moldiscovery.com/soft\\_pentacle.php](http://www.moldiscovery.com/soft_pentacle.php)
69. Eriksson L, Johansson E, Kettaneh-Wold N, Trygg J, Wikstrom C, Wold S. (Eds.) (2001) *Multi- and Megavariate Data Analysis. Basic Principles and Applications I*, 2nd ed, Umetrics Academy, Umeå
70. Tropsha A (2010) Best Practices for QSAR Model Development, Validation, and Exploitation. *Mol Inf* 29: 476–488
71. Cheng YC, Prusoff WH (1973) Relationship between the inhibition constant ( $K_i$ ) and the concentration of inhibitor which causes 50 per cent inhibition ( $IC_{50}$ ) of an enzymatic reaction. *Biochem Pharmacol* 22: 3099-3108
72. Scatchard G (1949) The attraction of proteins for small molecules and ions. *Ann NY Acad Sci* 51: 660-672

73. Schlegel JR, Peroutka SJ (1986) Nucleotide interactions with 5-HT<sub>1A</sub> binding sites directly labeled by [<sup>3</sup>H]-8-hydroxy-2-(di-n-propylamino)tetralin ([<sup>3</sup>H]-8-OH-DPAT). *Biochem Pharmacol* 35: 1943-1949
74. Herndon JL, Ismaiel A, Ingher SP, Teitler M, Glennon RA (1992) Ketanserin analogues: structure-affinity relationships for 5-HT<sub>2</sub> and 5-HT<sub>1C</sub> serotonin receptor binding. *J Med Chem* 35: 4903-4910
75. Buhot MC, Martin S, Segu L (2000) Role of serotonin in memory impairment. *Ann Med* 32: 210–21.
76. Roth BL, Hanizavareh SM, Blum AE (2004) Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. *Psychopharmacology (Berl)* 174: 17–24
77. Gray JA, Roth BL (2007) The pipeline and future of drug development in schizophrenia. *Mol Psychiatry* 12:904–922
78. Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel, A (2009) Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. *J Clin Psychiatry* 70:829–836
79. Patat A, Parks V, Raje S, Plotka A, Dietrich B (2005) Age–gender study of SRA-333, a novel 5-HT<sub>1A</sub> antagonist. *Clin Pharmacol Ther* 77: P29-P
80. Pitsikas N, Tsitsirigou S, Zisopoulou S, Sakellaridis N (2005) The 5-HT<sub>1A</sub> receptor and recognition memory. Possible modulation of its behavioral effects by the nitrenergic system. *Behav Brain Res* 159: 287–293
81. Schechter LE, Smith DL, Rosenzweig-Lipson S, Sukoff SJ, Dawson LA, Marquis K, Jones D, Piesla M, Andree T, Nawoschik S, Harder JA, Womack MD, Buccafusco J, Terry AV, Hoebel B, Rada P, Kelly M, Abou-Gharbia M., Barrett JE, Childers W (2005) Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. *J Pharmacol Exp Ther* 314: 1274–1289
82. Ballanger B, Klinger H, Eche J, Lerond J, Vallet AE, Le Bars D, Tremblay L, Sgambato-Faure V, Broussolle E, Thobois S (2012) Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease. *Movement Disorders* 27: 84-89
83. Wallace TL, Ballard TM, Pouzet B, Riedel WJ, Wettstein JG (2011) Drug targets for cognitive enhancement in neuropsychiatric disorders. *Pharmacol Biochem Be* 99: 130–145
84. Terry AV, Hoebel B, Rada P, Kelly M, Abou-Gharbia M., Barrett JE, Childers W (2005) Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. *J Pharmacol Exp Ther* 314: 1274-1289
85. Terry Jr AV, Buccafusco JJ, Bartoszyk GD (2005) Selective serotonin 5-HT<sub>2A</sub> receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys. *Psychopharmacology (Berl)* 179:725–732
86. Onogi H, Ishigaki S, Nakagawasai O, Arai-Kato Y, Arai Y, Watanabe H, Miyamoto A, Tan-No K, Tadano T (2009) Influence of memantine on brain monoaminergic neurotransmission parameters in mice: Neurochemical and behavioral study. *Biol Pharm Bull* 32: 850—855,

87. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ (2006) A 24-week open-label extension study of memantine in moderate to severe alzheimer disease. *Arch Neurology* 63: 49-54
88. Kim HS, Park IS, Park WK (1998) NMDA receptor antagonists enhance 5-HT<sub>2</sub> receptor-mediated behavior, head-twitch response, in mice. *Life Sci.* 63, 2305-2311
89. Nakagawasai O, Arai Y, Satoh SE., Satoh N, Neda M, Hozumi M, Oka R, Hiraga H, Tadano T (2004) Monoamine Oxidase and Head-Twitch Response in Mice Mechanisms of  $\alpha$ -Methylated Substrate Derivatives. *Neurotoxicology* 25: 223-232
90. Raddatz R, Tao M, Hudkins RL (2010) Histamine H<sub>3</sub> antagonists for treatment of cognitive deficits in CNS diseases. *Curr Top Med Chem* 10: 153–169

## List of Tables

**Table 1.** Compounds examined in this study [21-29].

**Table 2.** Experimental validation of the top ranked targets (PR-Scores $\leq$ 0.10) for the MAO/ChE inhibitors class (**44-100**). a) PR-Scores are derived by applying the cheminformatic methodology against the refined ChEMBL dataset.

**Table 3.** Experimental and 3D-QSAR validation of the top ranked targets for the MAO/ChE inhibitors class (**44-100**). a) PR-Scores are derived by applying the cheminformatic methodology against the refined ChEMBL dataset. b)  $pKi = \log(1/Ki)$ , Ki [M], c)  $Ki(5-HT_{1a}R) = 1.08 \times 10^{-7} \pm 0,04$  M,  $IC_{50}(5-HT_{1a}R) = 2.40 \times 10^{-7} \pm 0,10$  M,  $Ki(5-HT_{2a}R) = 1.42 \times 10^{-8} \pm 0.57$  M,  $IC_{50}(5-HT_{2a}R) = 1.92 \times 10^{-8} \pm 0.77$  M.

**Table 4.** Experimental validation of the top ranked targets (PR-Scores $\leq$ 0.10) for the H<sub>3</sub>R/HMT/ChE ligands (**101/1-Hetero-134/34-Hetero**). a) PR-Scores are derived by applying the cheminformatic methodology against the refined ChEMBL dataset.

**Table 5.** List of the top ranked targets predictions (PR-Scores $\leq$ 0.10) for the H<sub>3</sub>R/HMT/ChE ligands (**101/1-Hetero-134/34-Hetero**). a) PR-Scores are derived by applying the cheminformatic methodology against the refined ChEMBL dataset.

ID	Chemical scaffold	Experimentally determined activity on Target
<b>1-17</b>	carbonitrile, aminoheterocycles	MAO-A, MAO-B [7]
<b>18-77, 79-85</b>	acetylene, indol, piperidine	MAO-A, MAO-B, AChE, BuChE [8-11]
<b>78, 86-100</b>	pyridine	AChE, BuChE [12, 13]
<b>101-134</b>	quinoline, piperidine	H <sub>3</sub> R, HMT, AChE/BuChE (ID: 109, 128, 131, 133-134) [14, 15]

**Table 1.** Compounds examined in this study [21-29].

ID	Compound	Target (ChEMBL ID)	PR-Score <sup>a</sup>	Experimental - <i>K<sub>i</sub></i> [nM]	Experimental IC <sub>50</sub> [nM]
<b>45</b>	FA-97	MAO-B (2993)	0.00712	2.9 [11]	
		MAO-A (3358)	0.06270	18.8 [11]	
<b>48</b>	FA-66	MAO-B (2993)	0.01187	2.4 [11]	
		MAO-A (3358)	0.06659	5.4 [11]	
<b>52</b>	FA-65	MAO-B (2993)	0.00194	9.4 [11]	
		MAO-A (3358)	0.04900	18.0 [11]	
<b>54</b>	FA-67	MAO-B (2993)	0.02568	1.2 [11]	
		MAO-A (3358)	0.07348	26.5 [11]	
<b>55</b>	FA-73	MAO-B (2993)	0.00009	0.75 [11]	
<b>56</b>	Donepezil	AChE(4768)	0.00061	6.7 [10]	
		BuChE (5077)	0.00001	7400 [10]	
<b>58</b>	DonzD-4	MAO-A (3254)	0.04951		6.7 [10]
		MAO-B (2993)	0.01214		130 [10]
		AChE (220)	0.08021	420 [10]	
<b>59</b>	DonzD-5	MAO-A (3254)	0.05683		5.2 [10]
		MAO-B (2993)	0.01517		43 [10]
		AChE (220)	0.09698	350 [10]	
<b>59</b>	DonzD-6	MAO-A (3254)	0.06466		10 [10]
		MAO-B (2993)	0.01864		2700 [10]
		AChE (220)	0.07038	260 [10]	
<b>78</b>	Tacrine	AChE (3198)	0.00003	105 [15]	
		BuChE (3403)	0.00368	64 [15]	
		AChE (220)	0.02822		71 [13]
<b>95</b>	TP-10	AChE (220)	0.02542		58 [13]
<b>98</b>	TP-12	AChE (220)	0.02580		45 [13]

**Table 2.** Experimental validation of the top ranked targets (PR-Scores $\leq$ 0.10) for the MAO/ChE inhibitors class (**44-100**). a) PR-Scores are derived by applying the cheminformatic methodology against the refined ChEMBL dataset.

ID	Compound	Target (ChEMBL ID)	PR-Score <sup>a</sup>	3D-QSAR predicted – <i>pKi</i> <sup>b</sup> or Experimental- <i>pKi</i> <sup>c</sup>
31	PF96-Donz-D8	H <sub>3</sub> R (264)	0.07922	9.509 <sup>b</sup>
33	PF96-Donz-D10	H <sub>3</sub> R (264)	0.11912	10.137 <sup>b</sup>
34	PF96-Donz-D11	H <sub>3</sub> R (264)	0.05243	9.001 <sup>b</sup>
36	PF96-Donz-D13	H <sub>3</sub> R (264)	0.09145	10.472 <sup>b</sup>
57	DonzD-3	5-HT <sub>2a</sub> R (322)	0.14887	7.999 <sup>b</sup>
58	DonzD-4	5-HT <sub>2a</sub> R (322)	0.13293	7.057 <sup>b</sup>
59	DonzD-5	5-HT <sub>2a</sub> R (322)	0.14436	7.056 <sup>b</sup>
60	DonzD-6	5-HT <sub>2a</sub> R (322)	0.15002	7.522 <sup>b</sup>
62	DonzD-8	H <sub>3</sub> R (264)	0.14232	8.643 <sup>b</sup>
		D <sub>1</sub> R (265)	0.16686	6.928 <sup>b</sup>
		H <sub>3</sub> R (5299)	0.13534	9.646 <sup>b</sup>
63	DonzD-9	5-HT <sub>2a</sub> R (322)	0.11140	6.907 <sup>b</sup>
		D <sub>1</sub> R (265)	0.09508	6.903 <sup>b</sup>
		D <sub>2</sub> R (217)	0.07044	7.647 <sup>b</sup>
		H <sub>3</sub> R (264)	0.07044	10.105 <sup>b</sup>
67	MBA-50	D <sub>1</sub> R (265)	0.16648	6.448 <sup>b</sup>
68	MBA-71	H <sub>3</sub> R (4124)	0.10730	8.746 <sup>b</sup>
69	MBA-72	5-HT <sub>2a</sub> R (322)	0.10140	7.974 <sup>b</sup>
70	MBA-73	D1R (265)	0.12300	6.079 <sup>b</sup>
71	MBA-VEG8	5-HT <sub>1a</sub> R (273)	0.01827	6.967 <sup>c</sup>
		5-HT <sub>2a</sub> R (322)	0.02139	7.848 <sup>c</sup>
		D <sub>1</sub> R (265)	0.01073	6.580 <sup>b</sup>
82	TC4-MBA-91	5-HT <sub>2a</sub> R (322)	0.10597	7.566 <sup>b</sup>
83	TC5-MBA-98F1	5-HT <sub>2a</sub> R (322)	0.13397	7.360 <sup>b</sup>
84	TC-MBA-98F2	5-HT <sub>2a</sub> R (322)	0.13397	8.632 <sup>b</sup>
85	TC7-MBA-101	5-HT <sub>2a</sub> R (322)	0.12105	8.027 <sup>b</sup>

**Table 3.** Experimental and 3D-QSAR validation of the top ranked targets for the MAO/ChE inhibitors class (44-100). a) PR-Scores are derived by applying the cheminformatic methodology against the refined ChEMBL dataset. b)  $pKi = \log(1/Ki)$ ,  $Ki$  [M], c)  $Ki(5-HT_{1a}R) = 1.08 \times 10^{-7} \pm 0,04$  M,  $IC_{50}(5-HT_{1a}R) = 2.40 \times 10^{-7} \pm 0,10$  M,  $Ki(5-HT_{2a}R) = 1.42 \times 10^{-8} \pm 0.57$  M,  $IC_{50}(5-HT_{2a}R) = 1.92 \times 10^{-8} \pm 0.77$  M.



ID	Compound	Target (ChEMBL ID)	PR-Score <sup>a</sup>	E-Value
<b>106</b>	6-Hetero	HMT (3241)	0.01022	IC <sub>50</sub> =16 nM [14]
		H <sub>3</sub> R (264)	0.01998	Ki=411 nM [14]
<b>107</b>	7-Hetero	HMT (3241)	0.00887	IC <sub>50</sub> =49 nM [14]
		H <sub>3</sub> R (264)	0.01514	Ki=1130 nM [14]
<b>108</b>	8-Hetero	HMT (3241)	0.00704	IC <sub>50</sub> =590 nM [14]
		H <sub>3</sub> R (264)	0.00795	Ki=70 nM [14]
<b>109</b>	9-Hetero	AChE (4078)	0.00036	Ki=40.0 μM [15]
		BuChE (5077)	0.00031	Ki=25.4 μM [15]
		HMT(3241)	0.01466	IC <sub>50</sub> =45 nM [14]
		H <sub>3</sub> R (264)	0.01795	Ki=34 nM [14]
<b>118</b>	18-Hetero	HMT(3241)	0.00626	IC <sub>50</sub> =340 nM [14]
		H <sub>3</sub> R (264)	0.00965	Ki=3.6 nM [14]
<b>129</b>	29-Hetero	HMT (3241)	0.00046	IC <sub>50</sub> =420 nM [14]
		H <sub>3</sub> R (264)	0.01789	Ki=0.53 nM [14]
<b>130</b>	30-Hetero	HMT (3241)	0.00067	IC <sub>50</sub> =31 nM [14]
		H <sub>3</sub> R (264)	0.01424	Ki=0.75 nM [14]
<b>131</b>	31-Hetero	AChE (4078)	0.00789	IC <sub>50</sub> =8.6 nM [15]
		BuChE (5077)	0.00750	IC <sub>50</sub> =10.0 nM [15]
		HMT (3241)	0.01535	IC <sub>50</sub> =95 nM [14]
		H <sub>3</sub> R (264)	0.07511	Ki=1.4 nM [14]
<b>133</b>	33-Hetero	AChE (4078)	0.00235	IC <sub>50</sub> =3.1 nM [15]
		BuChE (5077)	0.00297	IC <sub>50</sub> =9.4 nM [15]
		HMT (3241)	0.01691	IC <sub>50</sub> =48 nM [14]
		H <sub>3</sub> R (264)	0.03693	Ki=1.8 nM [14]

**Table 4.** Experimental validation of the top ranked targets (PR-Scores≤0.10) for the H<sub>3</sub>R/HMT/ChE ligands (**101/1-Hetero-134/34-Hetero**). a) PR-Scores are derived by applying the cheminformatic methodology against the refined ChEMBL dataset.

ID	Compound	Target (ChEMBL ID)	PR-Score <sup>a</sup>	3D-QSAR predicted – <i>pKi</i> <sup>b</sup>
<b>102</b>	2-Hetero	5-HT <sub>2a</sub> R (322)	0.04929	6.488 <sup>b</sup>
		D <sub>2</sub> R (339)	0.06299	6.715 <sup>b</sup>
		Serotonin transporter (313)	0.06639	-
<b>106</b>	6-Hetero	H <sub>1</sub> R (231)	0.05799	-
<b>107</b>	7-Hetero	H <sub>1</sub> R (231)	0.04352	-
<b>108</b>	8-Hetero	H <sub>1</sub> R (231)	0.02623	-
<b>111</b>	11-Hetero	H <sub>1</sub> R (231)	0.01920	-
<b>118</b>	18-Hetero	H <sub>1</sub> R (231)	0.02817	-
<b>119</b>	19-Hetero	H <sub>1</sub> R (231)	0.00283	-
<b>130</b>	30-Hetero	H <sub>1</sub> R (231)	0.04670	-
<b>131</b>	31-Hetero	Beta amyloid A4 protein (2487)	0.01596	
		Glutamate [NMDA]R subunit zeta-1 (2015)	0.00374	
<b>132</b>	32-Hetero	H <sub>1</sub> R (231)	0.00760	-
		Beta amyloid A4 protein (2487)	0.00813	-
		Glutamate [NMDA]R subunit zeta-1 (2015)	0.00143	
<b>133</b>	33-Hetero	Beta amyloid A4 protein (2487)	0.00382	-
		Glutamate [NMDA]R subunit zeta-1 (2015)	0.00143	

**Table 5.** List of the top ranked targets predictions (PR-Scores $\leq$ 0.10) for the H<sub>3</sub>R/HMT/ChE ligands (**101/1-Hetero-134/34-Hetero**). a) PR-Scores are derived by applying the cheminformatic methodology against the refined ChEMBL dataset. b) *pKi* = log(1/Ki), Ki [M].

## List of Figures

**Figure 1.** General structural formulas of the examined compounds **1-134** [21-29]. Stereocenters are indicated with a star (\*).

**Figure 2.** Target prediction methodology applied for a query compound (**1-134**) using the refined ChEMBL dataset.

**Figure 3.** General structural formula of the indol derivatives used for 3D-QSAR(D<sub>1</sub>R), 3D-QSAR(D<sub>2</sub>R), and 3D-QSAR(5-HT<sub>2a</sub>) modeling.

**Figure 4.** Ligand-target associations for all examined compounds (**1-134**), obtained by querying the 134 compounds against the refined ChEMBL dataset.

**Figure 5.** Target prediction for **63/Donz-D9**.

**Figure 6.** Target prediction for **71/MBA-VEG8**.

**Figure 7.** Concentration-response curves of compound **71/MBA-VEG8** in *in vitro* assays for 5-HT<sub>1a</sub> (IC<sub>50</sub>  $2.40 \times 10^{-7} \pm 0.10$ ) (**A**) and for 5-HT<sub>2a</sub> (IC<sub>50</sub>  $1.92 \times 10^{-8} \pm 0.77$ ) (**B**) receptor binding. The curves were generated by non-linear regression to determine the IC<sub>50</sub> values. Data points are the mean  $\pm$  SD of triplicate values as described in Methods.

**Figure 8.** Chemical scaffolds of **63/Donz-D9**, **71/MBA-VEG8**, **102/2-Hetero**, haloperidol, and clozapine.

## List of Supplementary Tables


**Supplementary Table 1.** Ligand-target associations for all examined compounds (**1-134**), obtained by querying the 134 compounds against the refined ChEMBL dataset.

**Supplementary Table 2.** Ligand-pharmacological group associations for all examined compounds (**1-134**), obtained by querying the 134 compounds against the refined DrugBank dataset.


## List of Supplementary Figures

**Supplementary Figure 1.** Ligand-pharmacological group associations for all examined compounds (**1-134**), obtained by querying the 134 compounds against the refined DrugBank dataset.


Figure 1  
[Click here to download high resolution image](#)




**Cyano-derivatives (ID: 1-17)**  
target: MAO-A/B




**Indol-derivatives (ID: 44-55)**  
target: MAO-A/B



**Indol/Piperidine derivatives (ID: 18-43, 56-85)**  
target: MAO/ChE





**Pyridine derivatives (ID: 86-100)**  
target: ChE



**Quinoline/Piperidine derivatives (ID: 101-134)**  
target: H3R/HMTChE

Figure 2  
[Click here to download high resolution image](#)





**D<sub>1</sub>R/D<sub>2</sub>R/5-HT<sub>2a</sub>R ligands**



Figure 4  
[Click here to download high resolution image](#)




Figure 5  
[Click here to download high resolution image](#)

# Predicting activities for a molecule-ID: 1-100




Figure 6  
[Click here to download high resolution image](#)




Figure 7A  
[Click here to download high resolution image](#)




Figure 7B  
[Click here to download high resolution image](#)






Figure 8

[Click here to download high resolution image](#)



Electronic supplementary material-Table 1

[Click here to download Electronic supplementary material: SupplTable1-ID-1-134-Chembl.xls](#)

Electronic supplementary material-Table 2

[Click here to download Electronic supplementary material: SupplTable2-ID-1-134-DrugBank.xls](#)



Supplement Figure 1

[Click here to download Electronic supplementary material: 1 Supplement Figure-1-all-1-134-DrugBank-NEW.tif](#)